Alzheimer’s disease ppt
-
Upload
fariha-fatima -
Category
Health & Medicine
-
view
136 -
download
3
Transcript of Alzheimer’s disease ppt
![Page 1: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/1.jpg)
ALZHEIMER’S DISEASE:PATHOPHYSIOLOGY AND TREATMENT
Presented by: Fariha Fatima
JR-1
Department of Pharmacology
![Page 2: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/2.jpg)
INTRODUCTION:
• Alzheimer’s disease (AD) is the commonest progressive, dementing
neurodegenerative disease in elderly, which affects innumerable
people each year, and these numbers are likely to further increase as
the population ages.
• In addition to the financial burden of AD on health care system, the
disease has powerful emotional impact on caregivers and families of
those afflicted.
![Page 3: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/3.jpg)
Aloysius ”Alois” Alzheimer
• German psychiatrist
• Described symptoms + pathology• Neuronal loss• Plaques• Tangles
Cipriani et al. (2011) Neurological Sciences, 32(2), 275-279.
1864-1913
![Page 4: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/4.jpg)
![Page 5: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/5.jpg)
![Page 6: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/6.jpg)
![Page 7: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/7.jpg)
![Page 8: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/8.jpg)
![Page 9: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/9.jpg)
![Page 10: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/10.jpg)
PATHOPHYSIOLOGY:
• Alzheimer’s disease is characterized by the loss of neurons and
synapses in the cerebral cortex and certain subcortical regions.
• This loss results in gross atrophy of the affected regions , including
degeneration in the temporal lobe and parietal lobe and parts of frontal
cortex and cingulated gyrus.
![Page 11: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/11.jpg)
![Page 12: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/12.jpg)
![Page 13: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/13.jpg)
• The main pathological hallmarks of Alzheimer’s disease includes:
extracellular deposition of ß-amyloid (Aß) plaques,
intraneuronal neurofibrillary tangles.
Loss of cortical cholinergic neurones in AD probably accounts for
memory impairment.
![Page 14: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/14.jpg)
![Page 15: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/15.jpg)
![Page 16: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/16.jpg)
![Page 17: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/17.jpg)
• Further research, particularly in the genetic domain, led to
identification of APP and Presenilin genes (APP, PSEN1, and
PSEN2) and mutations in these genes as cause of rare forms of
early-onset familial AD.
• On other hand, ε4 allele of apolipoprotein E gene (APOE) has been
recognized as a major risk factor for late-onset AD.
![Page 18: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/18.jpg)
• Later, insight into the molecular pathogenesis of AD came
through many transgenic mouse models and tissue culture studies
of AD which led to the proposition of the “amyloid cascade
hypothesis”.
![Page 19: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/19.jpg)
![Page 20: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/20.jpg)
• However, there is growing evidence for the role of additional factors
such as oxidative stress, neuroinflammation, and mitochondrial
dysfunction in the pathogenesis of AD.
![Page 21: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/21.jpg)
DIAGNOSIS:
• Detailed patient history
• Information from family and friends
• Laboratory tests like:
Rule out vit B12 and folate deficiency
Rule out hypothyroidism with TFT tests
Blood cell count , serum electrolyte and LFT
• Other diagnostic tests:
CT, PET or MRI scans may aid diagnosis.
![Page 22: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/22.jpg)
![Page 23: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/23.jpg)
• Currently, clinical diagnosis of AD is based on the National Institute of
Neurological Disorders and Stroke—Alzheimer’s Disease and Related
Disorders Association (NINCDS–ADRDA) criteria.
• As the diagnostic criteria is based on the appearance of clinical
symptoms, the time when AD pathology has progressed sufficiently
they fail to detect subjects at preclinical stage.
![Page 24: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/24.jpg)
Therefore, there is a growing need for the development of measures
which can detect patients at an early stage.
Various biomarkers in AD can at least partly serve this purpose.
They can detect the patients with AD in their preclinical stage, monitor
the disease progression.
![Page 25: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/25.jpg)
![Page 26: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/26.jpg)
TREATMENT:
There is NO CURE for
Alzheimer’s disease!!!
![Page 27: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/27.jpg)
• Improving symptomatic decline by improving cognitive function, daily activities, and behavior
• Current therapy
• Arrests the neurodegenerative molecular process
• Research needed
Primary goals of therapy are:
![Page 28: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/28.jpg)
TARGETS OF DRUG ACTION FOR A.D.
![Page 29: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/29.jpg)
![Page 30: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/30.jpg)
![Page 31: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/31.jpg)
Future of AD Research
1. Symptomatic Treatments:
- Nicotinic-receptor Agonists/Antagonists
- Serotonin-receptor Agonists/Antagonists
2. Disease-modifying Treatments:
- Inhibition of amyloid formation
- beta and gamma-secretase inhibitors
- Inhibition of abeta aggregation
- Tau phosphorylation inhibitors
![Page 32: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/32.jpg)
The “Do-It-Yourself” Approach:
-Diet control
- Use of exercise
- Stress control
- Herbal remedies
![Page 33: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/33.jpg)
CONCLUSION:
• Cholinergic agents initially improve and transiently maintain cognitive
abilities in patients with mild-to-moderate AD.
• Cognitive abilities worsen over time, indicating treatment does not
stop (but may delay) the progression of AD.
• New treatments that maintain cognitive ability and stop the
progression of AD are needed .
![Page 34: Alzheimer’s disease ppt](https://reader033.fdocuments.in/reader033/viewer/2022051314/55a570071a28ab2c518b45d7/html5/thumbnails/34.jpg)